Hav­ing sold its cor­po­rate self, Toca­gen auc­tions off sci­en­tif­ic plat­form to San Diego biotech

With the der­mati­tis spe­cial­ists at Forte Bio­sciences now in­hab­it­ing Toca­gen’s cor­po­rate skele­ton, a small San Diego biotech has won rights to its sci­en­tif­ic plat­form.

De­n­o­vo Bio­phar­ma, a biotech based in San Diego and backed large­ly by in­vestors in Chi­na, will ac­quire Toca­gen’s retro-vi­ral repli­cat­ing plat­form, in­clud­ing their for­mer lead gene ther­a­py for brain can­cer. The drug, now re­brand­ed as DB107, failed a Phase III clin­i­cal tri­al last year, but De­n­o­vo said they saw promis­ing signs in a sub­set of pa­tients and will use their bio­mark­er plat­form to se­lect pa­tients they be­lieve the ther­a­py will work on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER